HHS sends the White House a peptide access policy for specialty pharmacies
HHS has sent the White House budget office an interim access policy on peptides, according to a posting on a government website. Two people familiar with the plan say it would assure pharmacies they will not be targeted for making certain peptides.
The Board Room · Leadership desk
Pharmacies would be assured they will not be targeted for certain peptides, people familiar with the plan say. FDA had listed BPC-157 as too risky to compound. FDA staff scientists said none had been studied enough. Formal listing would need federal rulemaking that could take years.
- Who's exposed exposure Compounding pharmacies Would be assured they will not be targeted for producing certain peptides, people familiar with the plan say, claim 17
- What it sets up precedent FDA Earlier listed BPC-157 as too risky to compound, citing contamination, allergic reactions, tumor growth, claim 4
- What doesn't add up contradiction FDA staff scientists Said none of the peptides had been studied enough to establish safety, against the outside advisers, claim 10
- What it limits constraint FDA safe-for-compounding list Formal listing would require federal rulemaking that could take years and multiple rounds of public comment, claim 11
| Who | How | Kind | Claim |
|---|---|---|---|
| Compounding pharmacies | Would be assured they will not be targeted for producing certain peptides, people familiar with the plan say | exposure | 17 |
| FDA | Earlier listed BPC-157 as too risky to compound, citing contamination, allergic reactions, tumor growth | precedent | 4 |
| FDA staff scientists | Said none of the peptides had been studied enough to establish safety, against the outside advisers | contradiction | 10 |
| FDA safe-for-compounding list | Formal listing would require federal rulemaking that could take years and multiple rounds of public comment | constraint | 11 |
What happened
- The same two people say the policy is meant to let pharmacies temporarily compound popular peptides, including BPC-157, a chemical promoted to build muscle and heal injuries.
- FDA had listed BPC-157, along with over a dozen other injectable peptides, as too risky to compound, citing contamination, allergic reactions and tumor growth.
- In July, outside advisers recommended dropping restrictions on six of seven peptides, against the view of FDA staff scientists that none had been studied enough.
- Formally adding peptides to the list of drugs safe for compounding would take federal rulemaking, which can run for years and includes multiple rounds of public comment.
Why it matters
- What it limits constraint An enforcement assurance leaves the compounding list unchanged, so any pharmacy relying on it depends on FDA continuing to choose not to act.
- Who has to decide decision Pharmacies deciding this quarter whether to add BPC-157 are acting on an unpublished policy, with no confirmation that the formal route that would settle the question is coming.
- Who's exposed exposure Buyers of pharmacy-made peptides would face the contamination, allergy and tumor-growth risks FDA itself listed, on evidence that is mostly animal data.
The peptide policy is now with the Office of Management and Budget, which reviews federal rules with the potential for significant economic impact [1][2]. The filing does not give specifics [15], so the description of its reach is secondhand [16]. HHS officials did not immediately respond to requests for comment on Thursday afternoon [14].
The policy follows a sequence Kennedy set in motion. Before joining the administration, he publicly declared that "FDA's war" on peptides and other wellness products would soon end [7]. Earlier this year he directed the agency to reconsider a short list of chemicals widely promoted by wellness influencers and fitness celebrities [5]. The panel of outside advisers that met in July was selected by his health department [12].
Kennedy's stated case is about the supply channel. As health secretary, he has argued that the country's compounding pharmacies must be permitted to sell peptides, because more and more Americans were buying "gray market" products made in China and other countries [6]. Those products remain widely available on platforms like TikTok [6]. FDA's staff scientists made a different point. They reiterated that none of the peptides had been studied enough to establish safety and effectiveness [10], and most of the existing data comes from animal studies [3]. In our view the two positions answer different questions: one is where people buy peptides, the other is whether the peptides are safe and effective. The sources do not include a comparison of pharmacy-made product with gray-market product.
The first public praise came from sellers. Brigham Buhler runs a wellness clinic and sells peptides through an online service. "This is huge," he wrote on X. "This isn't about whether you're for or against peptides. It's about whether you're for or against MEDICAL FREEDOM." [8] Some of the biggest MAHA figures sell peptide injections and supplements [9].
Sequencing is the open item. Enforcement discretion lets FDA selectively choose not to enforce some of its own regulations [17]. Formal listing would take rulemaking, and it was not immediately clear whether the administration still plans to pursue it [11][13]. A pharmacy that starts compounding BPC-157 this quarter on the interim assurance could still be relying on it next quarter, if no rulemaking follows. Its cover would be FDA's own decision not to enforce, and FDA is the agency whose staff scientists said in July that none of the peptides had been studied enough [17][10].
What to watch
- Whether OMB clears the policy and HHS publishes its text, which would show which peptides are covered and for how long.
- Whether HHS or FDA opens the rulemaking needed to add peptides to the list of drugs safe for compounding.
- Whether FDA staff scientists, who reiterated in July that none of the peptides had been studied enough, change that conclusion.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence50
- Adoption
- Not scored
- Hype gap+20
- Incentives75
- Confidence55
Perspective Coverage
3 publishers- Builder
- Builder 10%
- Operator
- Operator 67%
- Investor
- Investor 23%
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
HHS submitted a peptides "interim access policy" to the White House for review, according to a posting Thursday on a government website.
- [2]
The plan was sent to the Office of Management and Budget, which reviews federal rules and regulations with the potential for significant economic impact.
- [3]
The peptides at issue have not gone through rigorous vetting; their wellness uses are not approved by the FDA and most of the data on peptides comes from animal studies.
- [4]
The FDA previously placed BPC-157 and more than a dozen other injectable peptides on its list of substances too risky to be compounded by pharmacies; possible risks include contamination, allergic reactions and tumor growth, according to the FDA.
- [5]
Earlier this year, Kennedy directed the FDA to reconsider a short list of chemicals widely promoted by wellness influencers and fitness celebrities.
- [6]
After becoming health secretary, Kennedy said U.S. compounding pharmacies must be allowed to sell peptides because Americans were increasingly turning to "gray market" peptides made in China and other countries; those products remain widely available for purchase via online platforms like TikTok.
- [7]
Before joining the administration, Kennedy publicly declared that "FDA's war" on peptides and other wellness products would soon end.
- [8]
"This is huge," Brigham Buhler, a wellness clinic operator who sells peptides through an online service, posted on X. "This isn't about whether you're for or against peptides. It's about whether you're for or against MEDICAL FREEDOM."
- [9]
Some of the biggest MAHA figures sell peptide injections and supplements.
- [10]
In July, a panel of external FDA advisers recommended the agency drop its restrictions on six of the seven peptides put before them, going against the scientific conclusion of FDA staff scientists, who reiterated that none of the peptides had been studied enough to establish their safety and effectiveness.
- [11]
Formally adding the peptides to the FDA's list of drugs that are safe for compounding would require federal rulemaking, a process that could take years and involves multiple rounds of public comment.
- [12]
The panel of outside experts that met in July was selected by Kennedy's health department.
- [13]
It was not immediately clear if the administration still plans to pursue the federal rulemaking process for formally listing the peptides.
- [14]
HHS officials did not immediately respond to requests for comment Thursday afternoon.
- [15]
The White House filing does not give specifics of the new policy.
- [16]
Two people familiar with the plan, speaking anonymously to discuss confidential government deliberations, say it is intended to allow pharmacies to temporarily compound some of the most popular peptides, including BPC-157, a chemical promoted to build muscle and heal injuries.
- [17]
According to the people familiar with the plan, the policy would essentially assure compounding pharmacies that they will not be targeted for producing certain peptides. That approach, known as enforcement discretion, allows the FDA to selectively choose not to enforce some of its own regulations.
Get this ledger inside ChatGPT. Ask about any of our stories and the answer brings its figure, each claim’s verdict and the sources. Free, no account.
Sources
2 independent publishers whose own reporting we read for this story.
- abcnews.comTrump administration advances plan for peptide drugs favored by RFK Jr.
1 article · October 15, 2026
- arstechnica.comRFK Jr. proposes FDA look the other way on unproven peptides, report says
1 article · October 16, 2026
- statnews.comTrump administration advances plan for peptide drugs favored by RFK Jr.
1 article · October 15, 2026
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.
Entities
- Robert F. Kennedy Jr.Follow
- U.S. Department of Health and Human ServicesFollow
- Food and Drug AdministrationFollow
- Associated PressFollow
- Hims & HersFollow
- Office of Management and BudgetFollow
- NoomFollow
- BPC-157Follow